Spark Therapeutics Announces Closing of Public Offering
August 09, 2017 16:05 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today the closing of the previously announced underwritten public offering of its common...
Spark Therapeutics Announces Pricing of $350.0 Million Public Offering
August 03, 2017 19:18 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today the pricing of an underwritten public offering of 4,605,264 shares of its common...
Spark Therapeutics Announces Proposed Public Offering of Common Stock
August 02, 2017 17:04 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today that it has commenced an underwritten public offering of $300,000,000 in shares of...
Spark Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Progress
August 02, 2017 07:30 ET
|
Spark Therapeutics, Inc.
Preliminary interim data for SPK-8011 Phase 1/2 dose-escalation clinical trial in hemophilia A show initial human proof-of-concept in three participants In the two participants at the initial dose,...
Spark Therapeutics Submits Marketing Authorization Application to European Medicines Agency for Investigational LUXTURNA™ (voretigene neparvovec)
July 31, 2017 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, July 31, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
Spark Therapeutics to Host Conference Call on Wednesday, Aug. 2 at 8:30 a.m. ET to Discuss Second Quarter 2017 Results
July 28, 2017 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, July 28, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a...
Spark Therapeutics Receives Rare Pediatric Disease Designation for Investigational LUXTURNA™ (voretigene neparvovec) from FDA
July 20, 2017 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, July 20, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
Spark Therapeutics’ Biologics License Application for Investigational Voretigene Neparvovec Accepted for Filing by FDA
July 17, 2017 07:30 ET
|
Spark Therapeutics, Inc.
FDA grants Priority Review with Prescription Drug User Fee Act (PDUFA) date of Jan. 12, 2018 LUXTURNATM (voretigene neparvovec) unveiled as proposed trade name PHILADELPHIA, July 17, 2017 (GLOBE...
Spark Therapeutics Announces Publication in The Lancet of Pivotal Phase 3 Clinical Trial Data for Investigational Voretigene Neparvovec
July 13, 2017 18:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, July 13, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
Spark Therapeutics Presents Updated Interim Hemophilia B Data Supporting Consistent and Sustained Response at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress
July 10, 2017 11:47 ET
|
Spark Therapeutics, Inc.
Data demonstrate a 99-percent reduction in annualized infusion rate (AIR) and a 96-percent reduction in annualized bleeding rate (ABR) in 10 participants as of June 5, 2017 Five trial participants...